# Simile Series B

> Simile has raised a $200 million Series B at a $2 billion valuation, led by Greenoaks, just five months after a $100 million Series A. The founding team is notable in its own right, including Stanford's Joon Sung Park, Michael Bernstein, and Percy Liang, researchers behind some of the early work on AI agents that simulate human behavior. The product is synthetic users, AI simulations meant to predict how real people will react before a company acts. Simile's stated ambition is to eventually simulate all eight billion people on Earth, and it is building a confidence model that estimates how accurate any given simulation is, which is the sensible guardrail on an idea that could easily be oversold. The appeal to businesses is obvious, since testing a product or message on a simulated population is faster and cheaper than real research, and CVS Health Ventures is among the backers. The risk is just as obvious, because a simulation is only as good as its fidelity to messy human reality, and confidently wrong predictions could be worse than none. That the founders are building a confidence measure at all suggests they know it.

_Section: [AI Funding Tracker](https://www.wortins.com/funding) · Source: TechCrunch · Published Tuesday, August 11, 2026_

## Wortins' read

Simile has raised a $200 million Series B at a $2 billion valuation, led by Greenoaks, just five months after a $100 million Series A. The founding team is notable in its own right, including Stanford's Joon Sung Park, Michael Bernstein, and Percy Liang, researchers behind some of the early work on AI agents that simulate human behavior. The product is synthetic users, AI simulations meant to predict how real people will react before a company acts. Simile's stated ambition is to eventually simulate all eight billion people on Earth, and it is building a confidence model that estimates how accurate any given simulation is, which is the sensible guardrail on an idea that could easily be oversold. The appeal to businesses is obvious, since testing a product or message on a simulated population is faster and cheaper than real research, and CVS Health Ventures is among the backers. The risk is just as obvious, because a simulation is only as good as its fidelity to messy human reality, and confidently wrong predictions could be worse than none. That the founders are building a confidence measure at all suggests they know it.

## Source

[Read the full story at TechCrunch](https://techcrunch.com/2026/07/30/synthetic-user-startup-simile-raises-200m-at-2b-valuation-5-months-after-100m-series-a/)

## Related coverage

- [DARPA and US Air Force Successfully Fly F-16 Fighter Jet Under Full AI Control](https://www.wortins.com/story/darpa-and-us-air-force-successfully-fly-f-16-fighter-jet-und-b659da37) — [DARPA](https://www.darpa.mil/news/2026/darpa-us-air-force-fly-ai-controlled-f-16)
- [Hey Noah](https://www.wortins.com/story/hey-noah-c9c72973) — [Futurepedia](https://futurepedia.io/)
- [Cohere Launches Command A+ Mixture-of-Experts Model](https://www.wortins.com/story/cohere-launches-command-a-mixture-of-experts-model-5d840970) — [Cohere](https://docs.cohere.com/docs/command-a-plus)
- [Stripe Acquires OpenRouter for $7B+](https://www.wortins.com/story/stripe-acquires-openrouter-for-7b-2abe2a10) — [TechCrunch](https://techcrunch.com/2026/08/16/stripe-will-reportedly-acquire-ai-gateway-startup-openrouter-for-7b/)
- [Hike Medical Raises $22.5 Million Across Seed and Series A Funding](https://www.wortins.com/story/hike-medical-raises-22-5-million-across-seed-and-series-a-fu-111e6a0a) — [TechStartups](https://techstartups.com/2026/08/26/startup-funding-news-today-august-26-2026-emerald-ai-gatik-stellaria-more/)
- [AI Weakens Human Ability to Detect Fake News, Study Shows](https://www.wortins.com/story/ai-weakens-human-ability-to-detect-fake-news-study-shows-1dd22411) — [MIT Technology Review](https://www.technologyreview.com/2026/08/25/1140958/your-brain-on-ai/)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._